The seed investor High-Tech Gründerfonds (HTGF) finances tech start-ups with growth potential and has supported more than 700 start-ups since 2005. With the launch of its fourth fund, HTGF now has about 1.4 billion euros under management. Its team of experienced investment managers and start-up experts support young companies with expertise, entrepreneurial spirit and passion. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial tech, life sciences, chemistry and related business areas. To date, external investors have injected about 5 billion euros of capital into the HTGF portfolio via more than 2,000 follow-on financing rounds. In addition, HTGF has already successfully sold shares in more than 170 companies. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries. Fund investors in this public-private partnership include the German Federal Ministry for Economic Affairs and Climate Action, KfW Capital and 45 companies from a wide range of industries.
Avelios Medical operates a modular clinic platform designed to enhance patient care by digitizing and optimizing clinic processes. The platform offers user-friendly software that supports healthcare staff in their daily operations while facilitating the integration of innovative technologies such as artificial intelligence, big data, telemedicine, patient applications, and wearables. By streamlining workflows and automating various tasks, Avelios Medical aims to significantly improve both patient outcomes and healthcare research, making it a valuable resource for hospitals and clinics seeking to modernize their services.
Akribion Genomics
Seed Round in 2025
Akribion Genomics develops gene-editing tools and cancer therapies using CRISPR nuclease technology.
Laclarée
Seed Round in 2025
Laclarée Vision specializes in the development of adaptive eyeglasses designed to correct presbyopia. Founded in 2016 and based in Lyon, France, the company utilizes patented fluid technology to create lenses that automatically adjust in real-time to various viewing distances. This innovative approach addresses the needs of individuals aged 45 and older who often find traditional solutions, such as progressive lenses or multiple pairs of glasses, unsatisfactory. By combining adaptive lens technology with refractive correction for conditions like astigmatism, myopia, and hyperopia, Laclarée aims to provide a clearer vision experience for its users.
Lindis Blood Care
Venture Round in 2024
Lindis Blood Care´s mission is to optimise the outcome of cancer surgeries by developing a Medical Device to remove cancer cells from blood during cancer surgeries to enable Autologous Blood Transfusion.
Refoxy Pharma
Seed Round in 2024
Developer of therapeutic medicines intended to treat age-related diseases and improve healthy longevity. The company researches FOXO proteins that regulate multiple genes involved in processes like stress resistance, and metabolism and develops novel modulators of a central stress response pathway to modulate aging through genetics, enabling patients to extend the years of healthy living.
Doctorflix
Seed Round in 2024
Doctorflix is a medical education platform that allows doctors around the globe to learn about methods of treatment while accelerating their system-required professional development. We are on a mission to build an engine that simplifies and democratizes the consumption and exchange of medical knowledge by interlinking doctors, hospitals, and pharmaceutical companies.
Sedivention
Pre Seed Round in 2024
Sedivention is a medical technology startup that enables a one-time, interventional, and minimally invasive therapy for obesity. The company is developing a cryo catheter that ablates the gastric branches of the vagus nerve within minutes. As a one-time, minimally invasive procedure, the procedure can be performed in an outpatient setting, similar to a gastroscopy.
Lymphatica Medtech
Series B in 2024
Lymphatica Medtech SA is a Swiss company focused on designing and manufacturing medical devices for the treatment of lymphatic diseases, particularly lymphedema. Founded in 2017 and based in Lausanne, the company has developed LymphoDrain, an innovative medical device that aims to re-establish lymphatic circulation. This system includes an active implantable lymphatic bypass, featuring a magnetically controlled micropump and subcutaneous catheters that facilitate the internal drainage of lymphatic fluid from multiple points within the affected limb. Lymphatica Medtech also produces essential components for LymphoDrain, such as the micropump head and wearable controller, providing a minimally invasive solution for individuals suffering from persistent lymphedema.
BIOVOX
Seed Round in 2024
BIOVOX is a company that specializes in the development of biodegradable plastic components aimed at various industries, including medicine, hygiene, and food. By utilizing renewable, fully degradable, and recyclable raw materials, BIOVOX produces high-quality bioplastic compounds that offer an alternative to conventional plastics. The company's products are designed to help reduce carbon dioxide emissions, promoting an environmentally sustainable approach to materials in healthcare and beyond. Through its innovations, BIOVOX sets a standard in the sustainable healthcare market, encouraging clients to adopt more eco-friendly practices.
SciRhom
Series A in 2024
SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academic and industry scientists with profound experience in antibody development.
CustomSurg
Seed Round in 2024
Bone fractures involving a joint are complex in nature, resulting in difficult and time-consuming procedures for the treating orthopaedic surgeon. We provide fracture specific optimization of complex bone reconstruction. Our software solution ensures efficacy of personalized surgical planning, as well as “save and effective” patient-specific implant and instrument design, changing the treatment strategy from a subjective to an objective approach with more predictable outcomes. This could improve outcomes of 400,000 trauma patients, addressing a $1.2 B market. A Harvard Medical School surgeon directing the medical aspects, provides crucial credibility.
Tubulis
Series B in 2024
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.
Altavo
Series A in 2024
Altavo is a medical device startup focused on creating artificial voice solutions for individuals who have lost their ability to speak due to surgery or disease. By leveraging advanced machine learning and cutting-edge sensor technology, Altavo develops custom, natural-sounding voices that enable voiceless individuals to communicate effectively. The company's innovative approach combines speech recognition and synthesis, significantly enhancing the quality of life for those with speech disorders.
RAYDIAX
Seed Round in 2023
In order to enable minimally invasive medical interventions, RAYDIAX manufactures therapy-assist CT systems. The company's imaging solutions ensure safe, intuitive, and efficient procedures for patients and clinicians worldwide. The company's focus is to help health care providers to lower risk of postoperative complications and have patients require a shorter hospital stay and recovery time.
Inovedis
Series A in 2023
Inovedis specializes in medical technology, focusing on innovative solutions that enhance patient care while reducing time and costs in the healthcare sector. The company has developed a surgical device aimed at treating shoulder-based injuries more effectively. This device facilitates anatomical reconstruction of the physiological tendon-bone connection, helping to maintain metabolic function. By leveraging advanced technology, Inovedis enables surgeons to minimize the complexity of surgical techniques, ultimately providing greater relief to patients.
Kranus Health
Series A in 2023
Kranus Health is a prominent global provider of virtual care in the field of Urology, specializing in clinically validated therapies for various conditions, including those related to Andrology and Uro-Oncology. The company operates a digital health platform designed to assist men in overcoming issues such as erectile dysfunction and nausea. Through this platform, Kranus Health offers a comprehensive range of services, including pelvic floor training, cardiovascular training, mental health support, medical supervision, and preventive therapies. This approach empowers patients to manage their health conditions from the comfort of their homes, promoting healthier and longer lives.
InContAlert
Pre Seed Round in 2023
inContAlert is a deep tech start-up disrupting the field of incontinence. The technology of inContAlert helps people with bladder dysfunction to monitor the filling level of their urinary bladder. -- no more unnecessary catheters. no more needless emptying through nurses. no more diapers -- inContAlert, therefore, developed an mHealth device, which collects and analyzes data with the help of deep learning algorithms. The information is then displayed on an app and sends an alert to incontinence patients when a predefined filling level is reached. inContAlert thereby minimizes the risk of an uncontrolled loss of urine or the harmful distension of the bladder. With the help of inContAlert, incontinence patients can go back to normal and live a carefree life.
Doctorflix
Seed Round in 2023
Doctorflix is a medical education platform that allows doctors around the globe to learn about methods of treatment while accelerating their system-required professional development. We are on a mission to build an engine that simplifies and democratizes the consumption and exchange of medical knowledge by interlinking doctors, hospitals, and pharmaceutical companies.
Dualyx
Series A in 2023
Dualyx engages in the discovery and development of biologicals for the treatment of autoimmune and rare diseases.
Nia Health
Seed Round in 2023
Nia Health specializes in developing digital health applications that focus on dermatological conditions, particularly atopic dermatitis and psoriasis. The company utilizes an innovative MedTech platform to create personalized medical software that addresses the unique needs of each patient. Nia Health's AI-powered app offers tailored support and relief for individuals suffering from eczema, combining clinically validated content with features designed to enhance patient engagement. Originating from Charité Universitätsmedizin Berlin, the company aims to improve patient outcomes by providing effective treatments for chronic skin conditions while reducing the stigma associated with them. Nia Health has garnered significant funding, and its app is reimbursed by major health insurance providers in Germany.
DearEmployee
Seed Round in 2023
DearEmployee GmbH, founded in 2017 and based in Berlin, Germany, specializes in workplace mental health solutions. The company offers a software-as-a-service platform that enables employers to assess mental stress levels within their organizations in a scientific and digital manner. This platform supports the design of healthy and motivating work environments, aimed at reducing mental stress and enhancing employee productivity. Additionally, DearEmployee provides tailored health and human resources measures to address identified mental health issues. The solution also complies with legal requirements for mental health risk assessments in Germany, making it a valuable tool for organizations committed to employee wellbeing.
Mosanna Therapeutics
Seed Round in 2023
Mosanna is a Biotech company based in Basel with a commitment to improving patient outcomes and quality of life in high unmet need diseases, applying a precision medicine approach.
Selfapy
Venture Round in 2023
Selfapy GmbH is a Berlin-based company that specializes in developing online therapy programs aimed at individuals affected by depression and other psychological disorders. Since its founding in 2016, Selfapy has offered a range of programs addressing issues such as anxiety, eating disorders, stress, and chronic panic. The company provides users with a guided self-help experience, featuring exercises, videos, and texts delivered over a three-month period via phone or SMS. With a focus on recognizing negative thought patterns and promoting new behaviors, Selfapy's anonymous and flexible therapy solutions are designed to support users in managing their mental health effectively.
PraxisEins
Pre Seed Round in 2023
PraxisEins is a healthcare startup developing a software-enabled outpatient solution. They help doctors of all ages use modern technology to digitize their processes and reduce administrative pain.
Neotiv
Seed Round in 2022
Neotiv GmbH, founded in 2017 and headquartered in Magdeburg, Germany, specializes in mobile software solutions aimed at monitoring memory function and supporting individuals with dementia. The company offers memory tests designed to assess brain regions affected by aging and early Alzheimer's disease. Its health monitoring application not only tracks users' memory performance over time but also provides insights derived from scientific research, making them accessible to a wider audience. By combining neurodegenerative disease research with its digital platform, Neotiv enables healthcare professionals and researchers to enhance early detection and management of memory-related issues.
Kupando
Series A in 2022
Kupando is a biopharmaceutical company focused on developing TLR 4/7 agonists to enhance innate immunity. The company aims to provide cancer patients with safe and affordable immunotherapy while also creating immunostimulatory drugs to prevent infectious diseases. By targeting toll-like receptors that detect cancer and infection markers, Kupando’s therapies activate the innate immune system, allowing healthcare providers to effectively treat both cancer and infectious diseases.
FaCellitate
Seed Round in 2022
faCellitate develops polymeric platforms that aim at supporting cancer and stem cell research, drug discovery, toxicology, and tissue engineering. The platform facilitates cellular interaction, significantly improving cell culture in biological research.
C-mo Medical Solutions
Seed Round in 2022
C-mo is the solution providing a complete assessment of cough, adressing key use-cases across the patient management lifecycle.
Kranus Health
Series A in 2022
Kranus Health is a prominent global provider of virtual care in the field of Urology, specializing in clinically validated therapies for various conditions, including those related to Andrology and Uro-Oncology. The company operates a digital health platform designed to assist men in overcoming issues such as erectile dysfunction and nausea. Through this platform, Kranus Health offers a comprehensive range of services, including pelvic floor training, cardiovascular training, mental health support, medical supervision, and preventive therapies. This approach empowers patients to manage their health conditions from the comfort of their homes, promoting healthier and longer lives.
Invasight
Seed Round in 2022
Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.
Tubulis
Series B in 2022
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.
Lindis Blood Care
Venture Round in 2022
Lindis Blood Care´s mission is to optimise the outcome of cancer surgeries by developing a Medical Device to remove cancer cells from blood during cancer surgeries to enable Autologous Blood Transfusion.
Altavo
Seed Round in 2022
Altavo is a medical device startup focused on creating artificial voice solutions for individuals who have lost their ability to speak due to surgery or disease. By leveraging advanced machine learning and cutting-edge sensor technology, Altavo develops custom, natural-sounding voices that enable voiceless individuals to communicate effectively. The company's innovative approach combines speech recognition and synthesis, significantly enhancing the quality of life for those with speech disorders.
Newsenselab (M-sense)
Seed Round in 2021
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
Avelios Medical
Seed Round in 2021
Avelios Medical operates a modular clinic platform designed to enhance patient care by digitizing and optimizing clinic processes. The platform offers user-friendly software that supports healthcare staff in their daily operations while facilitating the integration of innovative technologies such as artificial intelligence, big data, telemedicine, patient applications, and wearables. By streamlining workflows and automating various tasks, Avelios Medical aims to significantly improve both patient outcomes and healthcare research, making it a valuable resource for hospitals and clinics seeking to modernize their services.
Alentis Therapeutics
Series B in 2021
Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.
PreComb
Seed Round in 2021
PreComb develops technologies to optimally adapt the therapies to each patient for difficult to treat cancers to increase the success rates in cancer therapy. Only an efficient use of healthcare resources can lead to a maximum improvement in the quality of life of patients.
Reactive Robotics
Venture Round in 2021
Reactive Robotics GmbH, founded in April 2015 and based in Gilching, Germany, specializes in the design, manufacture, and sale of rehabilitation robots aimed at early movement rehabilitation following neurological injuries and orthopedic surgeries. The company focuses on gait rehabilitation for neurological patients and assists orthopedic patients recovering from joint replacements. With a team that has over 12 years of experience in rehabilitation robotics, Reactive Robotics benefits from a robust clinical network and a group of advisors who provide guidance on engineering, legal matters, and medical device registration. Additionally, the company develops AI-driven robotic systems that support very early mobilization therapy, facilitating faster recovery for patients in intensive care units while alleviating the workload of nursing staff.
Actitrexx
Series A in 2021
ActiTrexx GmbH is a biotech start-up specializing in cellular therapy aimed at preventing inflammatory reactions associated with conditions such as graft-versus-host disease (GVHD), solid organ transplantation, and autoimmune diseases. The company's primary product, ATREGA, serves as a therapeutic option for patients who have undergone transplants, significantly enhancing survival rates. ActiTrexx focuses on developing and clinically testing cell therapeutics that help suppress transplant rejection and autoimmunity. By addressing the critical challenges of transplant rejection, the company's innovative therapies not only aim to improve patient survival but also enhance their overall quality of life and expand treatment options available to them.
Kranus Health
Seed Round in 2021
Kranus Health is a prominent global provider of virtual care in the field of Urology, specializing in clinically validated therapies for various conditions, including those related to Andrology and Uro-Oncology. The company operates a digital health platform designed to assist men in overcoming issues such as erectile dysfunction and nausea. Through this platform, Kranus Health offers a comprehensive range of services, including pelvic floor training, cardiovascular training, mental health support, medical supervision, and preventive therapies. This approach empowers patients to manage their health conditions from the comfort of their homes, promoting healthier and longer lives.
Lymphatica Medtech
Series A in 2020
Lymphatica Medtech SA is a Swiss company focused on designing and manufacturing medical devices for the treatment of lymphatic diseases, particularly lymphedema. Founded in 2017 and based in Lausanne, the company has developed LymphoDrain, an innovative medical device that aims to re-establish lymphatic circulation. This system includes an active implantable lymphatic bypass, featuring a magnetically controlled micropump and subcutaneous catheters that facilitate the internal drainage of lymphatic fluid from multiple points within the affected limb. Lymphatica Medtech also produces essential components for LymphoDrain, such as the micropump head and wearable controller, providing a minimally invasive solution for individuals suffering from persistent lymphedema.
heartbeat medical
Series A in 2020
Heartbeat enables providers to learn from the most important data point in healthcare: quality of life. We are experts in the field of Patient Reported Outcome Measures (PROMs) and passionate about generating high-quality Real World Evidence.
Tubulis
Series A in 2020
Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly transformative antibody-drug conjugates (ADCs). The company focuses on creating innovative chemotherapeutic medications that are specifically tailored to combat cancer and chronic disorders. By integrating proprietary technologies with disease-specific biology, Tubulis aims to identify novel protein-drug combinations that enable clinicians to treat cancer patients while minimizing the risks and side effects typically associated with traditional chemotherapy.
NovaPump
Series A in 2020
The NovaPump GmbH is a cardiology company based in Jena/Germany devoloping cutting-edge therapeutical solutions in the field of non-invasive and percutaneous circulation support. The so called PERKAT (PERKutane KATheterpumpe) technique will be offered as pLVAD & pRVAD heart pumps for acute left or right heart patients within the next years. PERKAT works together with the current IABP technique (intra aortic balloon pump with about 200,000 cases p.a. internationally) and is the only-one catheter-based & self-expanding, pulsatile & ECG-triggered, cost-effective heart pump technique with a high pump performance. PERKAT is not available on the market so far. Articles in leading scientific journals and presentations at the top four international cardiology conferences in the last years show the medical need, the development status and the technological and medical advantages of PERKAT.
Scipio Bioscience
Series A in 2020
Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.
Selfapy
Series A in 2020
Selfapy GmbH is a Berlin-based company that specializes in developing online therapy programs aimed at individuals affected by depression and other psychological disorders. Since its founding in 2016, Selfapy has offered a range of programs addressing issues such as anxiety, eating disorders, stress, and chronic panic. The company provides users with a guided self-help experience, featuring exercises, videos, and texts delivered over a three-month period via phone or SMS. With a focus on recognizing negative thought patterns and promoting new behaviors, Selfapy's anonymous and flexible therapy solutions are designed to support users in managing their mental health effectively.
Biograil
Seed Round in 2020
Biograil, founded in 2019 and led by CEO Karsten Lindhardt, specializes in developing a medical device that innovatively replaces traditional injection systems for administering medications. Utilizing an injection molding technique, the device is encapsulated in a standard-sized capsule and employs the body's natural peristaltic forces to deliver biologics directly into the gastrointestinal wall. This approach eliminates the need for mechanical moving components, allowing for a painless and efficient method of drug delivery to patients.
Mecuris
Series B in 2020
Mecuris strives to be the key enabler for digitally manufactured O&P solutions worldwide. They empower O&P professionals to co-create customised O&P products and enrich wearer’s lives within 24 hours.To reach this goal, they team up with O&P professionals to co-create - with users and wearers - customised O&P products. Their digital mindset and 3D printing know-how synergise in the Mecuris Solution Platform, which simplifies the work of O&P professionals and enriches wearers’ lives. The Mecuris Solution Platform uses patient data and scans to semi-automatically individualise 3D designs of patient aids. It makes them ready-to-print at a local 3D printing hub. This enables a 100% customised fit, functionality and look. They thereby cut production times by 75% for the medical practitioners and wearers.
DearEmployee
Venture Round in 2019
DearEmployee GmbH, founded in 2017 and based in Berlin, Germany, specializes in workplace mental health solutions. The company offers a software-as-a-service platform that enables employers to assess mental stress levels within their organizations in a scientific and digital manner. This platform supports the design of healthy and motivating work environments, aimed at reducing mental stress and enhancing employee productivity. Additionally, DearEmployee provides tailored health and human resources measures to address identified mental health issues. The solution also complies with legal requirements for mental health risk assessments in Germany, making it a valuable tool for organizations committed to employee wellbeing.
Lindis Blood Care
Venture Round in 2019
Lindis Blood Care´s mission is to optimise the outcome of cancer surgeries by developing a Medical Device to remove cancer cells from blood during cancer surgeries to enable Autologous Blood Transfusion.
Newsenselab (M-sense)
Seed Round in 2019
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
Laclarée
Seed Round in 2019
Laclarée Vision specializes in the development of adaptive eyeglasses designed to correct presbyopia. Founded in 2016 and based in Lyon, France, the company utilizes patented fluid technology to create lenses that automatically adjust in real-time to various viewing distances. This innovative approach addresses the needs of individuals aged 45 and older who often find traditional solutions, such as progressive lenses or multiple pairs of glasses, unsatisfactory. By combining adaptive lens technology with refractive correction for conditions like astigmatism, myopia, and hyperopia, Laclarée aims to provide a clearer vision experience for its users.
Draupnir Bio
Seed Round in 2019
Draupnir Bio intends to develop a new type of cholesterol-lowering medicine that prevents blood clots in the heart more effectively than the current medicine. The company is developing a platform for exploring the glycome to develop novel therapeutics, based on array technology, protein chemistry, and advanced carbohydrate chemistry. The company is able to synthesize, screen, and select highly potent and specific heparan sulfate glycomimetic drug candidates in cardiovascular, inflammatory, and infectious diseases.
miRdetect
Seed Round in 2019
miRdetect GmbH is a Bremen-based company that specializes in the development and marketing of in-vitro diagnostics for cancer detection. Founded in 2016, the company offers products such as miRcontrol GCT, a test kit specifically designed for the detection of testicular cancer. miRdetect focuses on creating and manufacturing molecular biological tests that enable the early identification and diagnosis of various cancers by accurately detecting minute quantities of nucleic acids. In addition to its existing products, the company is actively engaged in research and development to expand its portfolio of diagnostic tests.
Alentis Therapeutics
Series A in 2019
Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.
Cytena
Series A in 2019
Cytena GmbH is a biotechnology company based in Freiburg, Germany, specializing in the development of laboratory devices for the separation and printing of single cells. Founded in 2014, the company offers innovative products such as the cy-Clone and a range of single-cell printing technologies, which are essential for applications in drug development and genetic analysis, particularly in cancer and stem cell research. The cy-Clone utilizes an automated imaging process to encapsulate single cells in droplets, ensuring their viability and preventing cross-contamination through the use of disposable components. Cytena's technology enables efficient and contact-free deposition of cells on various substrates, facilitating the analysis and growth of clonal colonies. With a distribution network that spans Europe, North America, India, Asia, and the United Kingdom, Cytena operates as a subsidiary of Cellink AB, enhancing the capabilities of researchers and developers in the life sciences sector.
8sense
Seed Round in 2019
8sense is a developer of a physical coaching device that focuses on improving back health through a combination of position and movement analysis. The company offers a smart back sensor that provides real-time interaction and training, motivating users to prioritize their posture before issues arise. Utilizing a wearable device and a coaching platform, 8sense analyzes movements and posture, delivering personalized recommendations based on scientific principles. This innovative approach encourages users to adopt an active and dynamic sitting posture, thereby promoting better overall back health in office environments.
Eyeware
Seed Round in 2019
Eyeware Tech SA, founded in 2016 and based in Martigny, Switzerland, specializes in developing advanced eye and head tracking software, known as GazeSense, which utilizes consumer cameras. This innovative technology is applicable across a variety of sectors, including social robotics, automotive, healthcare, gaming, and advertising. As a research spin-off from EPFL and the Idiap Research Institute, Eyeware focuses on creating platform-independent solutions that leverage proprietary computer vision algorithms and machine perception AI. These advancements enable cost-effective and reliable eye tracking without the need for specialized hardware. Eyeware's software allows devices to understand user attention and intention, facilitating more natural interactions between people and technology. The company’s offerings are designed to support a wide range of applications, positioning Eyeware as a key player in the integration of human perception technology into everyday consumer devices and services.
Mecuris
Series A in 2019
Mecuris strives to be the key enabler for digitally manufactured O&P solutions worldwide. They empower O&P professionals to co-create customised O&P products and enrich wearer’s lives within 24 hours.To reach this goal, they team up with O&P professionals to co-create - with users and wearers - customised O&P products. Their digital mindset and 3D printing know-how synergise in the Mecuris Solution Platform, which simplifies the work of O&P professionals and enriches wearers’ lives. The Mecuris Solution Platform uses patient data and scans to semi-automatically individualise 3D designs of patient aids. It makes them ready-to-print at a local 3D printing hub. This enables a 100% customised fit, functionality and look. They thereby cut production times by 75% for the medical practitioners and wearers.
denovoMATRIX
Seed Round in 2018
denovoMATRIX GmbH specializes in the development and production of biomimetic coatings for stem cell culture, aiming to enhance cell manufacturing quality, quantity, and safety. Founded in 2018 and based in Dresden, Germany, the company offers products such as screenMATRIX, which facilitates various cellular functions including adhesion, differentiation, and organization, and myMATRIX, a custom-coated tissue cultureware designed for the growth of stem cells and primary cells in serum-free media. These innovative biomaterials are utilized in stem cell research, tissue modeling, and cell-based therapies, providing researchers with tailored solutions to address specific scientific inquiries and potential medical applications.
Amal Therapeutics
Series B in 2018
Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
GWA Hygiene
Venture Round in 2018
You can already profit from the Internet of Things (IOT) with the hygiene monitoring solutions by GWA Hygiene. With their solution you can capture your hand disinfection and (soon to come) your surface disinfection processes. They will equip your disinfectant / soap dispenser with their sensor technology. They will install a monitor to display your station's data and link the job groups via their attachable transponders. The data can be stored either on your in-house server, or their secure cloud server. Their software toolbox helps you analyze your processes and additionally facilitates everyday logistical tasks, such as filling the dispensers with disinfectant or replacing defective devices.
Newsenselab (M-sense)
Venture Round in 2018
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
Neotiv
Seed Round in 2018
Neotiv GmbH, founded in 2017 and headquartered in Magdeburg, Germany, specializes in mobile software solutions aimed at monitoring memory function and supporting individuals with dementia. The company offers memory tests designed to assess brain regions affected by aging and early Alzheimer's disease. Its health monitoring application not only tracks users' memory performance over time but also provides insights derived from scientific research, making them accessible to a wider audience. By combining neurodegenerative disease research with its digital platform, Neotiv enables healthcare professionals and researchers to enhance early detection and management of memory-related issues.
heartbeat medical
Venture Round in 2017
Heartbeat enables providers to learn from the most important data point in healthcare: quality of life. We are experts in the field of Patient Reported Outcome Measures (PROMs) and passionate about generating high-quality Real World Evidence.
Scipio Bioscience
Seed Round in 2017
Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.
RIMASYS
Venture Round in 2017
RIMASYS is the novel approach to surgical education and MedTech R&D. They enable medical science, academia, and the industry to develop better implants, and perform more advanced therapies, operations - with the aim to increase the quality of life for patients. RIMASYS is focusing on enhancing surgical education and improving patient outcomes by deploying realistic fractures for practical skill training and medical device development.
Reactive Robotics
Series B in 2017
Reactive Robotics GmbH, founded in April 2015 and based in Gilching, Germany, specializes in the design, manufacture, and sale of rehabilitation robots aimed at early movement rehabilitation following neurological injuries and orthopedic surgeries. The company focuses on gait rehabilitation for neurological patients and assists orthopedic patients recovering from joint replacements. With a team that has over 12 years of experience in rehabilitation robotics, Reactive Robotics benefits from a robust clinical network and a group of advisors who provide guidance on engineering, legal matters, and medical device registration. Additionally, the company develops AI-driven robotic systems that support very early mobilization therapy, facilitating faster recovery for patients in intensive care units while alleviating the workload of nursing staff.
Amal Therapeutics
Series B in 2017
Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
Selfapy
Seed Round in 2017
Selfapy GmbH is a Berlin-based company that specializes in developing online therapy programs aimed at individuals affected by depression and other psychological disorders. Since its founding in 2016, Selfapy has offered a range of programs addressing issues such as anxiety, eating disorders, stress, and chronic panic. The company provides users with a guided self-help experience, featuring exercises, videos, and texts delivered over a three-month period via phone or SMS. With a focus on recognizing negative thought patterns and promoting new behaviors, Selfapy's anonymous and flexible therapy solutions are designed to support users in managing their mental health effectively.
SciRhom
Seed Round in 2017
SciRhom GmbH is a biotech company that translates science into the preclinical and early clinical development of novel biopharmaceuticals for the treatment of life-threatening autoimmune diseases. Based on longstanding academic research and a well-established network of experts, SciRhom was founded in 2016 through a collaboration between academic and industry scientists with profound experience in antibody development.
Whitesonic
Seed Round in 2016
The company intends to use the funds to further develop its scanner. A prototype can be used on patients as early as 2017. Approval as a medical product should then be obtained upon the completion of an evaluation phase
Newsenselab (M-sense)
Venture Round in 2016
M-sense is a certified medical app to combat migraines and headache. Our goal is to reduce 50% of headache days through a personalized therapy program - all in-app.
Mecuris
Seed Round in 2016
Mecuris strives to be the key enabler for digitally manufactured O&P solutions worldwide. They empower O&P professionals to co-create customised O&P products and enrich wearer’s lives within 24 hours.To reach this goal, they team up with O&P professionals to co-create - with users and wearers - customised O&P products. Their digital mindset and 3D printing know-how synergise in the Mecuris Solution Platform, which simplifies the work of O&P professionals and enriches wearers’ lives. The Mecuris Solution Platform uses patient data and scans to semi-automatically individualise 3D designs of patient aids. It makes them ready-to-print at a local 3D printing hub. This enables a 100% customised fit, functionality and look. They thereby cut production times by 75% for the medical practitioners and wearers.
Immunic Therapeutics
Series A in 2016
Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies for chronic inflammatory and autoimmune diseases. The company has a pipeline that includes three small molecule products. Its lead program, IMU-838, is a selective immune modulator that works by inhibiting the enzyme DHODH, targeting conditions such as multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. The second product, IMU-935, functions as an inverse agonist of the transcription factor RORγt and is being developed for psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Lastly, IMU-856 aims to restore intestinal barrier function and is intended for diseases associated with bowel barrier dysfunction. Through these innovative therapies, Immunic Therapeutics aims to address significant unmet medical needs in the field of immunology.
Rigontec
Series A in 2016
Rigontec is the leader in RIG-I targeting RNA therapeutics developing novel immuno-oncology treatment options.
CryoTherapeutics
Series B in 2016
CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in developing a proprietary cryotherapy system aimed at treating coronary artery disease, which is a leading cause of heart attacks. The company focuses on demonstrating clinical benefits and advancing early-stage commercialization of its innovative catheter system that employs cryoenergy to address issues related to diseased coronary arteries. By proving the safety and efficacy of cryoenergy in the cardiovascular context, CryoTherapeutics aims to provide heart surgeons with an effective tool to prevent heart attacks and enhance patient outcomes.
Reactive Robotics
Series A in 2016
Reactive Robotics GmbH, founded in April 2015 and based in Gilching, Germany, specializes in the design, manufacture, and sale of rehabilitation robots aimed at early movement rehabilitation following neurological injuries and orthopedic surgeries. The company focuses on gait rehabilitation for neurological patients and assists orthopedic patients recovering from joint replacements. With a team that has over 12 years of experience in rehabilitation robotics, Reactive Robotics benefits from a robust clinical network and a group of advisors who provide guidance on engineering, legal matters, and medical device registration. Additionally, the company develops AI-driven robotic systems that support very early mobilization therapy, facilitating faster recovery for patients in intensive care units while alleviating the workload of nursing staff.
Amal Therapeutics
Series A in 2016
Amal Therapeutics SA is a biotechnology company based in Geneva, Switzerland, founded in 2012 as a spin-off from the University of Geneva. The company specializes in the research and development of therapeutic vaccines for oncology, utilizing a proprietary cell penetrating peptide platform. Amal Therapeutics focuses on creating peptide-based vaccines that generate cellular immune responses, including the activation of killer T cells that target tumor cells and promote long-lasting immunological memory. This approach aims to enhance the efficacy of cancer treatments and improve outcomes for patients. As of July 2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.
heartbeat medical
Venture Round in 2016
Heartbeat enables providers to learn from the most important data point in healthcare: quality of life. We are experts in the field of Patient Reported Outcome Measures (PROMs) and passionate about generating high-quality Real World Evidence.
LifeTime
Seed Round in 2016
LifeTime is a digital health application developed by connected-health.eu GmbH since 2014, which has established itself as a leading and secure solution for the digital management and transmission of medical data. The application facilitates the efficient and accurate exchange of medical documents, including findings and images, between healthcare professionals and patients. By enabling secure digital communication, LifeTime enhances the clarity of health and treatment histories for users, streamlining workflows for doctors and medical staff. In 2019, LifeTime GmbH acquired the platform, signaling a new phase of development and enhancement under its management.
Bomedus
Series B in 2015
Bomedus is a Germany-based medical device company established in 2011, focused on improving mobility for individuals suffering from chronic pain, particularly back pain. The company's innovative devices employ an electro-therapeutic method aimed at providing permanent and sustainable pain reduction. By non-invasively modulating pathologically altered neuronal impulses, Bomedus seeks to enhance the quality of life for patients experiencing chronic discomfort.
Eyetronic Therapie
Venture Round in 2015
EBS Technologies is a medical device company that has developed a stimulation system for the treatment of neurologically caused impairments such as visual field loss. Such impairments can be the result of stroke, traumatic-brain-injury, glaucoma or several other diseases. The EBS Therapy (previously: NEXT WAVE™Therapy) is a non-invasive optic nerve stimulation deploying weak electrical currents, resulting in neuroregeneration and neuroprotection. Low-voltage electrical pulses are administered at frequencies and amplitudes identified as optimal for each patient, allowing retinal ganglion cells to regenerate and branch out new axons. The company benefits from more than 15 years of research and clinical experience with more than 1,200 patients. Double blind, randomized studies, as well as clinical observations show that the EBS Therapy can partially restore vision field in patients. In 2013 EBS Technologies received the CE Mark for the stimulation device and started the commercial treatment in 2014. There are currently 8 EBS Treatment centers across Germany and the company is slowly widening the network.
Cytena
Seed Round in 2015
Cytena GmbH is a biotechnology company based in Freiburg, Germany, specializing in the development of laboratory devices for the separation and printing of single cells. Founded in 2014, the company offers innovative products such as the cy-Clone and a range of single-cell printing technologies, which are essential for applications in drug development and genetic analysis, particularly in cancer and stem cell research. The cy-Clone utilizes an automated imaging process to encapsulate single cells in droplets, ensuring their viability and preventing cross-contamination through the use of disposable components. Cytena's technology enables efficient and contact-free deposition of cells on various substrates, facilitating the analysis and growth of clonal colonies. With a distribution network that spans Europe, North America, India, Asia, and the United Kingdom, Cytena operates as a subsidiary of Cellink AB, enhancing the capabilities of researchers and developers in the life sciences sector.
Sonormed GmbH
Series A in 2015
Sonormed GmbH is a medical technology company focusing on digital audiology.
Oncgnostics
Series A in 2015
Oncgnostics GmbH, founded in 2012 and based in Jena, Germany, specializes in developing molecular assays that leverage epigenetic biomarkers for early and reliable cancer diagnostics. The company focuses on in vitro diagnostic (IVD) tests that aid in screening, therapeutic decision-making, and follow-up care in cancer treatment. Notably, Oncgnostics has developed GynTect, a diagnostic tool that facilitates the swift and accurate detection of cervical cancer and its precancerous stages. The tests are based on identifying specific DNA regions that are methylated in cancerous and precancerous cells, utilizing established PCR-based technologies suitable for routine molecular diagnostic laboratories. Through its innovative approach, Oncgnostics aims to enhance cancer diagnosis and improve patient outcomes.
Rigontec
Series A in 2014
Rigontec is the leader in RIG-I targeting RNA therapeutics developing novel immuno-oncology treatment options.
medineering
Seed Round in 2014
Medineering is a medical technology company based in Munich, Germany, specializing in innovative robotic systems for minimally invasive head surgery. Founded in 2014, the company develops, patents, and sells a modular range of surgical manipulators that enable clinics and surgeons to customize the level of automation and functionality based on their specific surgical needs and budget constraints. Its product portfolio includes an intelligent positioning arm and compact, application-specific robots designed to assist surgeons in navigating complex anatomical regions. Medineering aims to enhance the potential of minimally invasive surgery through advanced robotic solutions that optimize surgical access and improve working conditions in the operating room.
Desino
Series A in 2014
Desino, based in Cologne, Germany, specializes in developing adaptive wheelchairs that incorporate a dynamic seating system. These innovative wheelchairs are designed to combine traditional handrail features with effortless lever propulsion, facilitating long-distance mobility. By addressing the needs of individuals who spend extended periods in seated positions, Desino's products promote continuous spinal motion and engage back muscles, mimicking the natural movement of walking. This approach aims to enhance comfort and reduce back strain, offering users a more dynamic and supportive seating experience.
Coramaze Technologies
Seed Round in 2014
Coramaze Technologies is a medical device company focused on developing innovative solutions for heart diseases. Founded in 2013 and headquartered in Munich, Germany, the company is working on a minimally invasive valve repair system aimed at treating patients with structural heart valve diseases. Their flagship product, the Mitramaze valve repair system, is a catheter-based device designed for implantation directly into the beating heart, catering to inoperable and asymptomatic patients. Additionally, Coramaze is advancing an adaptive tricuspid valve repair device known as Tripair, which is designed to be anchored in the right atrium, facilitating a quick and straightforward procedure accessible in catheterization labs. This technology aims to address functional mitral regurgitation resulting from heart enlargement due to conditions like heart attacks or heart failure, thus providing less invasive treatment options for patients who might otherwise go without proper care.
Scopis
Series A in 2013
Scopis is a developer and manufacturer of clinical navigation system for image guided surgery specializing in laser-based measuring and endoscopic augmented reality. Scopis was founded in August 2010 as a joint spin-off of Charité University Clinic Berlin and Fraunhofer IPK. It received an immediate seed round from German incubator High Tech Gründerfonds (HTGF). The MATRIX POLAR navigation system range was brought on the European market in January 2011. Scopis has since focused on improving the utility of navigation for endoscopic procedures. Notably, the Augmented Reality navigation product MATRIX POLAR AR was launched in August 2011.
Synoste
Venture Round in 2013
Synoste Oy, founded in 2007 and based in Espoo, Finland, specializes in developing innovative solutions for the treatment of skeletal deformities. The company focuses on patient-friendly technologies for various conditions, including congenital limb discrepancies, trauma-related injuries, and craniomaxillofacial deformities. Its flagship product is a third-generation limb-lengthening system that incorporates smart materials, designed to enhance patient comfort during the often-complicated lengthening procedure. This advanced device aims to reduce complications and facilitate quicker recovery, making it a significant improvement over traditional methods. As a subsidiary of Globus Medical, Inc., Synoste continues to advance its mission of providing effective and less painful treatment options for individuals with skeletal deformities.
Photonics Healthcare
Venture Round in 2013
Photonics Healthcare GmbH is a medical device company based in Garching, Germany, specializing in the development and commercialization of clinical monitors for measuring cellular oxygen levels. Its primary product, the COMET Monitor, enables healthcare professionals to non-invasively assess cellular oxygen metabolism, including both availability and consumption, at the bedside. This technology is crucial for detecting hypoxia in tissue cells, allowing doctors to evaluate tissue vitality and make informed decisions regarding treatment interventions. By providing real-time data on cellular oxygen dynamics, Photonics Healthcare supports the timely prevention of organ failure and aims to enhance patient care. Additionally, the company offers contract research programs to further advance its medical technologies.
NovaPump
Seed Round in 2013
The NovaPump GmbH is a cardiology company based in Jena/Germany devoloping cutting-edge therapeutical solutions in the field of non-invasive and percutaneous circulation support. The so called PERKAT (PERKutane KATheterpumpe) technique will be offered as pLVAD & pRVAD heart pumps for acute left or right heart patients within the next years. PERKAT works together with the current IABP technique (intra aortic balloon pump with about 200,000 cases p.a. internationally) and is the only-one catheter-based & self-expanding, pulsatile & ECG-triggered, cost-effective heart pump technique with a high pump performance. PERKAT is not available on the market so far. Articles in leading scientific journals and presentations at the top four international cardiology conferences in the last years show the medical need, the development status and the technological and medical advantages of PERKAT.
Middle Peak Medical
Series A in 2013
Middle Peak Medical is a privately held medical device company focused on the development and commercialization of a novel technology to treat mitral valve disease. The company’s proprietary device has application in both percutaneous catheter-based intervention, and in minimally invasive or open-heart cardiac surgery.
Eyetronic Therapie
Series B in 2013
EBS Technologies is a medical device company that has developed a stimulation system for the treatment of neurologically caused impairments such as visual field loss. Such impairments can be the result of stroke, traumatic-brain-injury, glaucoma or several other diseases. The EBS Therapy (previously: NEXT WAVE™Therapy) is a non-invasive optic nerve stimulation deploying weak electrical currents, resulting in neuroregeneration and neuroprotection. Low-voltage electrical pulses are administered at frequencies and amplitudes identified as optimal for each patient, allowing retinal ganglion cells to regenerate and branch out new axons. The company benefits from more than 15 years of research and clinical experience with more than 1,200 patients. Double blind, randomized studies, as well as clinical observations show that the EBS Therapy can partially restore vision field in patients. In 2013 EBS Technologies received the CE Mark for the stimulation device and started the commercial treatment in 2014. There are currently 8 EBS Treatment centers across Germany and the company is slowly widening the network.
Dolosys
Venture Round in 2013
Dolosys GmbH is a medical device company focused on the development and production of equipment for the objective measurement of pain and analgesia.
CardioSecur
Series A in 2013
CardioSecur, a subsidiary of Personal MedSystems, focuses on innovative mobile health solutions, particularly in the realm of instant cardiac monitoring. The company has developed a smartphone-based ECG application that includes a specialized set of electrodes for efficient data collection. This application allows users to conduct personalized cardiac monitoring and facilitates the sharing of results with healthcare providers, enabling patients to receive timely recommendations on their health status in under a minute. By prioritizing ease of use and sophisticated design, CardioSecur aims to deliver professional-grade ECG technology for individuals, enhancing personal health management.
CryoTherapeutics
Series A in 2013
CryoTherapeutics GmbH, founded in 2009 and based in Cologne, Germany, specializes in developing a proprietary cryotherapy system aimed at treating coronary artery disease, which is a leading cause of heart attacks. The company focuses on demonstrating clinical benefits and advancing early-stage commercialization of its innovative catheter system that employs cryoenergy to address issues related to diseased coronary arteries. By proving the safety and efficacy of cryoenergy in the cardiovascular context, CryoTherapeutics aims to provide heart surgeons with an effective tool to prevent heart attacks and enhance patient outcomes.
Epivios
Venture Round in 2012
Epivios GmbH, founded in 2011 and based in Düsseldorf, Germany, specializes in molecular diagnostics aimed at the early detection of bladder and prostate cancer. As a spin-off from Heinrich Heine University, the company has an interdisciplinary team of doctors and biologists who have been developing innovative epigenetic procedures for cancer diagnosis since 2009. Epivios has created a unique epigenetic platform technology that features a novel standardization tool, allowing for the comparison of samples with varying genetic constitutions. This advancement enables more accurate analysis of genetic sequences across the entire genome, contributing to improved diagnostic capabilities in the field of oncology.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.